—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
DRUG DISCOVERY TODAY《当代药物发现》
月刊 - 英国
  • DRUG DISCOVERY TODAY《当代药物发现》
  • SCIE外文期刊
  • 期发文量25
  • 国人占比26.67%
  • 维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:2区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:7
    环比增速:-44.44%
  • 期刊信息

  • 研究方向:医学-PHARMACOLOGY PHARMACY 药学
  • 国际刊号:ISSN1359-6446;EISSN1878-5832
  • 期刊语言:英语
    出版地区:英国
  • 投稿网址:https://www.editorialmanager.com/DRUDIS
  • 电子邮箱:
  • 期刊官网:https://www.journals.elsevier.com/drug-discovery-today
  • 作者指南:
  • 出版商网址:http://www.elsevier.com
  • 出版地址:ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB
  • 期刊简介:DRUG DISCOVERY TODAY《当代药物发现》(月刊). Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.

  • 万维提示


  • 1、投稿方式:在线投稿

    2期刊网址:http://www.drugdiscoverytoday.com/

    https://www.journals.elsevier.com/drug-discovery-today

    3期刊网址:https://www.editorialmanager.com/DRUDIS

    4、官网邮箱:ddt@drugdiscoverytoday.com

    5、期刊刊期:月刊,一年出版12期。

    2021年8月19日星期

                                     

     

    投稿须知【官网信息】

     

    Guide for Authors

    Aims and scope

    Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.

    Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.

    Coverage includes:

    Novel therapeutic strategies

    High-throughput screening

    Therapeutic targets

    Combinatorial chemistry, parallel synthesis and library design

    Drug delivery

    ADME/Tox

    Advances in key compound classes and therapeutic areas

    Genomics and proteomics

    Automation and technology

    Virtual chemistry

    Informatics

    Business strategy

    Clinical trials

    and other aspects of drug discovery.

    Ethics in Publishing: General Statement

    The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

    For more information, please refer to: https://www.elsevier.com/conflictsofinterest

    Submission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at: http://www.drugdiscoverytoday.com/submit-a-paper/

    ……

    更多详情:

    https://www.elsevier.com/journals/drug-discovery-today/1359-6446/guide-for-authors



欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码